Delving into the Latest Updates on L-Arginine/L-Aspartate with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

ARGININE ASPARTATE

Target-

Action-

Mechanism-

Therapeutic Areas

Other DiseasesMouth and Tooth Diseases

Active Indication-

Inactive Indication

InflammationPeriodontitis

Originator Organization-

Active Organization-

Inactive Organization

Ukrainian Medical Stomatological Academy

License Organization-

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H21N5O6

InChIKeySUUWYOYAXFUOLX-ZBRNBAAYSA-N

CAS Registry3054-35-1

This randomized clinical trial and laboratory study was conducted to:
Compare the effectiveness of zinc-carbonated nano-hydroxyapatite, arginine, and fluoride-containing toothpastes for treating white spot lesions associated with orthodontically treated teeth by using:
Computerized image software analysis.
Energy dispersive X-ray analysis.

Start Date30 Nov 2023

Sponsor / Collaborator

Mansoura University

NCT06135792

/ CompletedNot ApplicableIIT

The Effect of Arginine on Biofilm Composition, Architecture and Metabolism in Caries-active Patients: a Split-mouth in Situ Trial

Arginine is an adjunct to oral health care that has the potential to modulate the composition and activity of the microbial community of dental biofilms towards a health-related status without harmful effects for the resident oral microbiota. The aim of the study is to investigate the effects of arginine treatment compared to placebo on the composition, metabolism, and microarchitecture of biofilms grown in situ in the oral cavity of caries-active participants.

Start Date19 Oct 2023

Sponsor / Collaborator

University of Aarhus

NCT02440061

/ WithdrawnPhase 1IIT

Ghrelin Effect on Beta Cell Function in Health and Disease #2

Ghrelin is a hormone naturally produced in the stomach and the gut. The purpose of this research study is to determine the role of this gut hormone in the regulation of insulin secretion from the pancreas and glucose disposal after we eat. The investigators hypothesize that ghrelin has an effect on the pancreas and on how our body handles glucose after we eat. The investigators will compare insulin secretion and glucose changes during meal ingestion while either acyl ghrelin (AG) or saline (salt solution) is being infused through your vein on separate study days. AG is a form of the ghrelin hormone that has a small modification to it that allows it to bind to a specific receptor. The investigators hypothesize that AG has an effect on how the body handles glucose after a meal. AG has been approved by the U.S. Food and Drug Administration (FDA) for human research only. This study will also involve the use of a medicine called arginine, which is a naturally occurring product and found in many nutritional supplements. Its use in this study is investigational. The use of arginine helps maximize insulin release from the pancreas so the investigators can better examine whether AG affects insulin secretion.

Start Date01 May 2018

Sponsor / Collaborator

Duke University

[+1]

100 Clinical Results associated with L-Arginine/L-Aspartate

Login to view more data

100 Translational Medicine associated with L-Arginine/L-Aspartate

Login to view more data

100 Patents (Medical) associated with L-Arginine/L-Aspartate

Login to view more data

70

Literatures (Medical) associated with L-Arginine/L-Aspartate

01 Aug 2024·Journal of Pharmaceutical Sciences

Designing Robust Monoclonal Antibody Drug Products: Pitfalls of Simplistic Approaches for Stability Prediction

Article

Author: Gokarn, Yatin R ; Saluja, Atul ; Rembert, Kelvin B

Thermal stability attributes including unfolding onset (T_onset) and mid-point (T_m) are often utilized for efficient development of monoclonal antibody (mAb) products during lead selection and formulation screening workflows. An assumption of direct correlation between thermal and kinetic physical stability underpins this basic approach. While literature reports have substantiated this general approach under specific conditions, clear exceptions have been highlighted alongside. Herein, a set of mAbs formulated under diverse solution conditions to generate a broad array of thermal and kinetic stability profiles were systematically analyzed. Sequence modifications in the Fc region were purposefully engineered to generate a set of low-melting mAbs. A diverse set of excipients were subsequently utilized and shown to modulate the T_m over a wide range. While a general correlation between high T_m and low aggregation rate was observed under accelerated conditions, the predictive utility of T_m under relevant product storage conditions was inadequate at best. Critically, T_m data did not correlate with long-term aggregation rates under refrigerated or room temperature conditions. Even under accelerated conditions, T_m appeared to be a poor predictor of aggregation once it exceeded the solution storage temperature (40°C) by ∼15°C, similar to conditions routinely encountered in the development of canonical mAbs (T_m > 60°C). Pitfalls of simplistic correlative approaches are discussed in the context of practical biologics product development.

01 Aug 2024·Nature Structural & Molecular Biology

Mechanism of autocatalytic activation during proteasome assembly

Article

Author: Adams, Lea ; Huang, Lan ; Perez, Erignacio Fermin ; Blickling, Marie ; Razi, Aida ; Rajakumar, Tamayanthi ; Jiao, Fenglong ; Fung, Darlene ; Walsh, Richard M ; Rawson, Shaun ; Hanna, John ; Velez, Benjamin

Many large molecular machines are too elaborate to assemble spontaneously and are built through ordered pathways orchestrated by dedicated chaperones. During assembly of the core particle (CP) of the proteasome, where protein degradation occurs, its six active sites are simultaneously activated via cleavage of N-terminal propeptides. Such activation is autocatalytic and coupled to fusion of two half-CP intermediates, which protects cells by preventing activation until enclosure of the active sites within the CP interior. Here we uncover key mechanistic aspects of autocatalytic activation, which proceeds through alignment of the β5 and β2 catalytic triad residues, respectively, with these triads being misaligned before fusion. This mechanism contrasts with most other zymogens, in which catalytic centers are preformed. Our data also clarify the mechanism by which individual subunits can be added in a precise, temporally ordered manner. This work informs two decades-old mysteries in the proteasome field, with broader implications for protease biology and multisubunit complex assembly.

01 Oct 2023·Heliyon

Prophylaxis of decidual CD68+/CD163+ macrophage disbalance in extracorporeal fertilized women

Article

Author: Akimov, Oleh ; Taranovska, Olena ; Likhachov, Volodymyr ; Shimanska, Yanina ; Kaidashev, Igor ; Zhabchenko, Iryna ; Vashchenko, Viktoriya

The demographic crisis that prevailed in Ukraine in recent years, the state of war as a result of the aggression of the Russian Federation, reproductive losses among women of childbearing age are one of the most urgent problems in modern obstetrics and gynecology. One of the most effective methods of correcting impaired reproductive function is in vitro fertilization.The purpose of this workis to develop a pharmacological complex for the prevention of imbalance of CD68⁺/CD163⁺ decidual macrophages in vitro fertilized women.Materials and methods105 pregnant women who were divided into 3 groups took part in the study. The first group included 20 women whose pregnancy occurred and is proceeding physiologically. The second group consisted of 85 women who became pregnant as a result of in vitro fertilization, including 37 pregnant women who refused prophylactic correction of the threat of premature birth, and 48 pregnant women who received prophylactic correction of the threat of premature birth: complex prescription of vitamin D3 2000 IU orally 2 times a day, micronized progesterone 200 mg 2 times a day and l-arginine aspartate 1000 mg 4 times a day, starting from 18 to 20 weeks of pregnancy.ResultsIn women who refused prophylactic correction of the threat of premature birth, a local increase in the activity of inducible NO-synthase and concentration of tumor necrosis factor-α, and a decrease in the activity of arginase and in the level of interleukin-10 were observed in the cervical mucus. They have a lower expression of CD163⁺ on placental decidual macrophages and an increased expression of CD68⁺, which indicates a shift in the polarization of macrophages from an anti-inflammatory to a pro-inflammatory phenotype. The use of prophylactic treatment brings the studied parameters closer to the results of women in whom pregnancy occurred physiologically.ConclusionsIn women who became pregnant as a result of in vitro fertilization, at 28-30 weeks of pregnancy, changes specific for pro-inflammatory phenotype of decidual macrophages were observed. Complex administration of vitamin D3, micronized progesterone and l-arginine aspartate lead to restoration of anti-inflammatory phenotype of decidual macrophages.

100 Deals associated with L-Arginine/L-Aspartate

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Phase 3	Ukraine	Ukrainian Medical Stomatological Academy	20 Oct 2017
Periodontitis	Phase 3	Ukraine	Ukrainian Medical Stomatological Academy	20 Oct 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2018	Not Applicable	Metabolic Syndrome	62	L-Arginine aspartate	cwcofefypi(ggicyrbdyu) = susdfacqva pndsvggkoi (fheowyejmv ) View more	-	26 Aug 2018
				l-arginine aspartate	cwcofefypi(ggicyrbdyu) = dpchgalaur pndsvggkoi (fheowyejmv ) View more
EULAR2015	Not Applicable	Rheumatoid Arthritis \| Hypertension	42	L-Arginine aspartate + standard treatment	(pwczczariy) = djyshjythy pjttbtywid (eojpoyofzm )	Positive	10 Jun 2015
				Standard treatment	(pwczczariy) = hecdwweyvo pjttbtywid (eojpoyofzm )
FP098 (ERA2015)	Not Applicable	Renal Insufficiency \| Rheumatoid Arthritis \| Hypertension	27	L-Arginine aspartate 30 ml/day	(mwerbmqrbz) = gnnoncrfga ueeegmtfog (kxhkttpiid ) View more	Positive	21 May 2015
				Standard treatment	(mwerbmqrbz) = fgpsdupvpn ueeegmtfog (kxhkttpiid ) View more
EULAR2011	Not Applicable	Rheumatoid Arthritis	40	Methotrexatum	dqgivqrgpj(nzonbuwxfm) = gvewwemusq pjgnvrzswn (swrddgwpzv ) View more	Positive	25 May 2011
				NO-donators (Arginine hydrochloride and L-Arginine aspartate)	dqgivqrgpj(nzonbuwxfm) = ftnxklgeys pjgnvrzswn (swrddgwpzv )